Beyond systemic lupus erythematosus: a systematic review on the use of belimumab in other connective tissue diseases and vasculitides
The SLR showed that data on the use of belimumab in rheumatic conditions, other than SLE, are still scarce. However, belimumab may have therapeutic potential in specific subsets of patients with rheumatic diseases characterized by aberrant B cell activation. Future research should focus on large, randomized phase 3 trials with extended follow-up to better define the role of belimumab in rheumatic diseases beyond SLE, particularly in combination with standard-of-care therapies.
Authors
- Caterina Vacchi (ORCID: https://orcid.org/0000-0003-1702-9582)
- O. Secchi (ORCID: https://orcid.org/0009-0005-4954-9728)
- Martina Orlandi (ORCID: https://orcid.org/0000-0001-6784-2235)
- Dilia Giuggioli (ORCID: https://orcid.org/0000-0002-0041-3695)
- F. Santoro (ORCID: https://orcid.org/0009-0006-2169-0954)
- Giulia Cassone (ORCID: https://orcid.org/0000-0002-3454-401X)
- Maria Grazia Malandra
Institutions
- University of Modena and Reggio Emilia (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
Publication Details
- Journal
- Clinical Rheumatology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1007/s10067-025-07847-5
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00